Holen Sie sich die Stockscreener-App
2.05
1.49%
0.03
Handel nachbörslich:
2.05
Black Diamond Therapeutics Inc Aktie (BDTX) Neueste Nachrichten
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX? - StockInvest.us
Black Diamond Settles HMI Cancer-Drug Discovery Patent Lawsuit - news.bloomberglaw.com
Weekly Recap: Silevertinib NSCLC Phase 2 efficacy and $110.5M cash runway - TradingView
Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX - MarketBeat
Black Diamond Therapeutics Inc (BDTX) Stock News Today - TradingKey
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $14 - Moomoo
Black Diamond Therapeutics Inc (BDTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 Earnings Forecast for BDTX Issued By HC Wainwright - MarketBeat
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $11 - Moomoo
Raymond James Reaffirms Outperform on BDTX Amid Promising NSCLC Trial Data - GuruFocus
Jefferies Optimistic on BDTX Ahead of Q4 Catalysts; Shares Trade Near 1-Year Low - GuruFocus
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating - Moomoo
Black Diamond Therapeutics (NASDAQ:BDTX) Posts Earnings Results - MarketBeat
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Black Diamond Therapeutics reports Q2 2026: $110.5M cash, $9.9M net loss - TradingView
Black Diamond Therapeutics, Inc. 2Q 2026: Revenue $0 Net income ($9.91M), EPS ($0.17) — 10-Q Summary - TradingView
Black Diamond Therapeutics Q2 net loss narrows year over year - TradingView
BDTX: Silevertinib demonstrated robust Phase 2 efficacy in NSCLC, supporting pivotal development plans - TradingView
Black Diamond Therapeutics (NASDAQ: BDTX) details Q2 loss and 2028 cash runway - Stock Titan
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Black Diamond Therapeutics Q2 net loss narrows to $9.91 million; revenue remains no revenue - Bitget
BDTX Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Black Diamond Therapeutics Inc (BDTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Black Diamond Therapeutics (BDTX) Expected to Post Earnings on Thursday - MarketBeat
BDTX|Black Diamond Therapeutics Inc|Price:1.730|Chg%:-0.030 - TradingKey
Black Diamond Therapeutics (BDTX): BlackRock discloses 3.84M-share, 6.7% ownership - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Black Diamond Therapeutics, Inc. Revenue Breakdown – NASDAQ:BDTX - TradingView
Black Diamond Therapeutics Inc (BDTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.760|Chg%:-0.080 - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.770|Chg%:+0.040 - TradingKey
Black Diamond Therapeutics Inc (BDTX) Balance Sheet - TradingKey
Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Black Diamond Therapeutics Inc (BDTX) Cash Flow - TradingKey
TradingKey - TradingKey
Black Diamond Therapeutics Inc (BDTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Trading Down 1.1%Here's What Happened - MarketBeat
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary - Quartr
Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support TestSeasonality Effect - dars.gov.et
BDTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Development Progress ContinuesConsensus Beat Rate - dars.gov.et
T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment - Stock Titan
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth - simplywall.st
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali - Moomoo
Black Diamond Therapeutics touts Silevertinib lung cancer data, eyes FDA path - MSN
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash - Moomoo
Black Diamond Therapeutics 2026 Annual Stockholder Meeting Results and Voting Outcomes - Minichart
Form 4 Black Diamond Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity - Stock Titan
Black Diamond (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) director awarded 40,000 stock options at $1.71 - Stock Titan
Director Garry Menzel granted 40,000 BDTX stock options at $1.71 strike - Stock Titan
Black Diamond (NASDAQ: BDTX) director receives 40,000 stock options at $1.71 - Stock Titan
Black Diamond Therapeutics (BDTX) awards 40,000-share option grant - Stock Titan
Black Diamond Therapeutics (BDTX) 2026 meeting backs directors, auditor and annual say-on-pay - Stock Titan
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) added to Russell 2000 Index - marketscreener.com
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Value Benchmark - marketscreener.com
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):